JP2008527988A5 - - Google Patents

Download PDF

Info

Publication number
JP2008527988A5
JP2008527988A5 JP2007551749A JP2007551749A JP2008527988A5 JP 2008527988 A5 JP2008527988 A5 JP 2008527988A5 JP 2007551749 A JP2007551749 A JP 2007551749A JP 2007551749 A JP2007551749 A JP 2007551749A JP 2008527988 A5 JP2008527988 A5 JP 2008527988A5
Authority
JP
Japan
Prior art keywords
growth factor
bacterium
protein
csf
cytokines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007551749A
Other languages
English (en)
Japanese (ja)
Other versions
JP4989490B2 (ja
JP2008527988A (ja
Filing date
Publication date
Priority claimed from GBGB0501540.9A external-priority patent/GB0501540D0/en
Application filed filed Critical
Publication of JP2008527988A publication Critical patent/JP2008527988A/ja
Publication of JP2008527988A5 publication Critical patent/JP2008527988A5/ja
Application granted granted Critical
Publication of JP4989490B2 publication Critical patent/JP4989490B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007551749A 2005-01-25 2006-01-24 腸内細菌による生物活性物質の制御された産生および送達 Expired - Fee Related JP4989490B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0501540.9A GB0501540D0 (en) 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria
GB0501540.9 2005-01-25
PCT/GB2006/000222 WO2006079790A2 (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria

Publications (3)

Publication Number Publication Date
JP2008527988A JP2008527988A (ja) 2008-07-31
JP2008527988A5 true JP2008527988A5 (https=) 2012-05-10
JP4989490B2 JP4989490B2 (ja) 2012-08-01

Family

ID=34259652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007551749A Expired - Fee Related JP4989490B2 (ja) 2005-01-25 2006-01-24 腸内細菌による生物活性物質の制御された産生および送達

Country Status (10)

Country Link
US (1) US7988961B2 (https=)
EP (1) EP1841875B1 (https=)
JP (1) JP4989490B2 (https=)
KR (1) KR101291960B1 (https=)
AT (1) ATE483811T1 (https=)
CA (1) CA2640343C (https=)
DE (1) DE602006017331D1 (https=)
ES (1) ES2353721T3 (https=)
GB (1) GB0501540D0 (https=)
WO (1) WO2006079790A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008317000B2 (en) * 2007-10-26 2014-10-23 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
EP2258844A1 (en) 2009-05-28 2010-12-08 Helmholtz Zentrum Für Infektionsforschung Tumour-specific bacterial promoter elements
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
WO2015095796A1 (en) 2013-12-20 2015-06-25 President And Fellows Of Harvard College An engineered genetic enteric sensor bacteria and uses thereof
US10610546B2 (en) 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
AU2015369627A1 (en) * 2014-12-22 2017-07-06 Massachusetts Institute Of Technology Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
BR112017018656B1 (pt) * 2015-03-02 2021-11-30 Synlogic, Inc Bactéria geneticamente modificada, composição farmaceuticamente aceitável compreendendo a dita bactéria e uso da dita composição para tratar ou prevenir uma doença ou condição associada à inflamação intestinal e/ou função da barreira intestinal comprometida
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017087580A1 (en) 2015-11-16 2017-05-26 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia
AU2017252409B2 (en) 2016-04-20 2023-08-24 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
WO2018112194A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
US11224624B2 (en) * 2017-02-14 2022-01-18 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior and disease
US20200268813A1 (en) * 2017-02-15 2020-08-27 President And Fellows Of Harvard College Modulation of host immune cell populations using gut microbiota
WO2018183685A1 (en) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
JP2020516318A (ja) * 2017-04-17 2020-06-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 操作された共生細菌及び使用方法
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
JP2022512380A (ja) 2018-12-10 2022-02-03 ノヴォム バイオテクノロジーズ,インコーポレイテッド 高シュウ酸尿症を治療するための方法及び組成物
CN115298308A (zh) 2020-03-20 2022-11-04 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569604A1 (en) 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
JP2003509046A (ja) * 1999-09-10 2003-03-11 イギリス国 組換え微生物
JP2001275680A (ja) * 2000-03-31 2001-10-09 Yakult Honsha Co Ltd β−1,3−キシラナーゼ遺伝子、該遺伝子を導入した微生物、及びβ−1,3−キシラナーゼの製造法
JP2003144200A (ja) * 2001-11-07 2003-05-20 Yakult Honsha Co Ltd バクテロイデスグループ細菌用プローブおよびこれを用いた検出方法

Similar Documents

Publication Publication Date Title
JP2008527988A5 (https=)
CN1195860C (zh) 生物学活性多肽的输送
JP2011500842A5 (https=)
KR101291960B1 (ko) 장내세균에 의한 생물학적 활성제의 제어된 생산 및 전달
Lillehoj et al. Resistance to intestinal coccidiosis following DNA immunization with the cloned 3-1E Eimeria gene plus IL-2, IL-15, and IFN-γ
Qiao et al. Recombinant lactic acid bacteria as promising vectors for mucosal vaccination
Vallittu et al. Clinical guide to principles of fiber-reinforced composites in dentistry
WO1988000971A1 (en) Recombinant vaccine
BRPI0806578A2 (pt) Promotores de lactococcus e usos dos mesmos
CN102380091A (zh) 白介素-22在治疗病毒性肝炎中的应用
Scuderi et al. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis
US20210338741A1 (en) Tissue healing agent
Collins et al. Cloning and expression of bovine and porcine interleukin-2 in baculovirus and analysis of species cross-reactivity
Yang et al. Metabolic engineering of Lactobacilli spp. for disease treatment
US20050025806A1 (en) Sustained release pharmaceutical composition
Tarpey et al. Expression of chicken interleukin-2 by turkey herpesvirus increases the immune response against Marek's disease virus but fails to increase protection against virulent challenge
CN103702680A (zh) 采用快速滴定递增剂量方案用于降低与肌肉内施用干扰素有关的流感样症状的方法
Park et al. Immunomodulatory effects of mixed Weissella cibaria JW15 with water extract of black soybean and burdock on Listeria monocytogenes infection in mice.
Zarkovic Gjurin et al. Zirconia ceramic fixed partial dentures after cyclic fatigue tests and clinical evaluation: a systematic review
Jenkins et al. Effectiveness and durability of common weight loss methods
WO2023185442A1 (zh) 葡萄糖调控基因表达环路控制系统及其调控血糖的应用
Thomas et al. Expression, purification and characterisation of recombinant Escherichia coli derived chicken interleukin-12
Dunham et al. Isolation, expression and bioactivity of feline granulocyte–macrophage colony-stimulating factor
RU98109522A (ru) Доставка биологически активных полипептидов
Kim et al. Co‐administration of live attenuated Salmonella enterica serovar Typhimurium expressing swine interleukin‐18 and interferon‐α provides enhanced Th1‐biased protective immunity against inactivated vaccine of pseudorabies virus